| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 4197.0 | 3303.0 | 2959.0 |
| Other income | -17.0 | -13.0 | -18.0 |
| Total income | 4180.0 | 3290.0 | 2941.0 |
| Profit before exceptional items & tax | 595.0 | 824.0 | 689.0 |
| Exceptional items | 66.0 | 10.0 | 24.0 |
| Profit before tax | 529.0 | 814.0 | 665.0 |
| Net profit | 364.0 | 635.0 | 498.0 |
| Operating margin | 12.7% | 24.7% | 22.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -26.90% |
|---|---|
| Net profit, quarter on quarter | -42.70% |
| Revenue, year on year | +41.80% |
BSE results filing, NSE: TORNTPHARM. Figures extracted from the filing.
Torrent Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,988.50
- Market cap
- ₹1,89,747 Cr
- Revenue (annual)
- ₹13,980 Cr
- Net profit (annual)
- ₹2,163 Cr
- P/E (TTM)
- 87.0×Sector 50.4×
- Promoter holding
- 60.78%-7.53% QoQ
- FII holding
- 17.97%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Torrent Pharmaceuticals Ltd
All →Torrent Pharmaceuticals Annual General Meeting
Shareholders approved the appointment of Ms. Shanti Ekambaram as an Independent Director of Torrent Pharmaceuticals via Postal Ballot.
Torrent Pharmaceuticals Earnings Call Transcript: Key Takeaways
Torrent Pharma delivered strong Q1 performance with revenues up 55% following the JB Chemicals merger completion. EBITDA margins jumped to 33.8% driven by accelerated cost synergies.
- Call
- Guides 10% growth
Torrent Pharmaceuticals Q1 FY27 Results: Net Profit ₹566 Cr, Up 3.3% YoY
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,921 Cr (+54.8% YoY) and net profit of ₹566 Cr (+3.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹566 Cr · +3.3% YoY
Torrent Pharmaceuticals Earnings Call: Key Takeaways
Torrent Pharma Q4 FY26 revenue rose 42% to ₹4,197cr, driven by JB Pharma consolidation. Combined EBITDA margin stood at 32.3%, with focus on Semaglutide ramp-up in India and synergy execution.
Torrent Pharmaceuticals Earnings Call: Key Takeaways
Torrent Pharma delivered strong Q4 growth led by India and Brazil, while successfully integrating Curatio and JB Pharma assets.